OBJECTIVE: To look for the association of tissue matrix metalloproteinase 9 (MMP-9) expression with dynamic contrast-enhanced magnetic resonance imaging and to see whether these can prognosticate patients with glioblastoma multiforme (GBM). METHODS: Forty-seven patients with GBM underwent dynamic contrast-enhanced magnetic resonance imaging to look for association of its indices with tissue MMP-9 expression using Pearson correlation. Kaplan-Meier survival analysis was performed to study the survival pattern for low-, medium-, and high-tissue MMP-9 expression and kep values. RESULTS: Among perfusion indices, kep, k, and ve significantly correlated with MMP-9 expression. Matrix metalloproteinase 9 expression was found to be best estimated by kep using a quadratic model. The 1-year survival in low-, medium-, and high-tissue MMP-9 and kep groups were 59%, 45%, and 7%, and 59%, 33%, and 15%, respectively. CONCLUSION: The association of kep and MMP-9 expression with survival suggests that kep may be used as imaging biomarker of GBM progression and its prognostication.
OBJECTIVE: To look for the association of tissue matrix metalloproteinase 9 (MMP-9) expression with dynamic contrast-enhanced magnetic resonance imaging and to see whether these can prognosticate patients with glioblastoma multiforme (GBM). METHODS: Forty-seven patients with GBM underwent dynamic contrast-enhanced magnetic resonance imaging to look for association of its indices with tissue MMP-9 expression using Pearson correlation. Kaplan-Meier survival analysis was performed to study the survival pattern for low-, medium-, and high-tissue MMP-9 expression and kep values. RESULTS: Among perfusion indices, kep, k, and ve significantly correlated with MMP-9 expression. Matrix metalloproteinase 9 expression was found to be best estimated by kep using a quadratic model. The 1-year survival in low-, medium-, and high-tissue MMP-9 and kep groups were 59%, 45%, and 7%, and 59%, 33%, and 15%, respectively. CONCLUSION: The association of kep and MMP-9 expression with survival suggests that kep may be used as imaging biomarker of GBM progression and its prognostication.
Authors: R K Gupta; R Awasthi; R K Garg; N Kumar; P K Gupta; A K Singh; P Sahoo; V K Paliwal; K N Prasad; C M Pandey; R K S Rathore Journal: AJNR Am J Neuroradiol Date: 2012-11-22 Impact factor: 3.825
Authors: Y S Choi; D W Kim; S-K Lee; J H Chang; S-G Kang; E H Kim; S H Kim; T H Rim; S S Ahn Journal: AJNR Am J Neuroradiol Date: 2015-09-03 Impact factor: 3.825
Authors: T B Nguyen; G O Cron; J F Mercier; C Foottit; C H Torres; S Chakraborty; J Woulfe; G H Jansen; J M Caudrelier; J Sinclair; M J Hogan; R E Thornhill; I G Cameron Journal: AJNR Am J Neuroradiol Date: 2014-06-19 Impact factor: 3.825
Authors: Anna K Heye; Ross D Culling; Maria Del C Valdés Hernández; Michael J Thrippleton; Joanna M Wardlaw Journal: Neuroimage Clin Date: 2014-09-10 Impact factor: 4.881
Authors: Michelle Roytman; Sean Kim; Shannon Glynn; Charlene Thomas; Eaton Lin; Whitney Feltus; Rajiv S Magge; Benjamin Liechty; Theodore H Schwartz; Rohan Ramakrishna; Nicolas A Karakatsanis; Susan C Pannullo; Joseph R Osborne; Jonathan P S Knisely; Jana Ivanidze Journal: Front Oncol Date: 2022-01-28 Impact factor: 6.244